Rifaquizinone (CBR-2092) is a rifamycin-quinolone hybrid antibiotic that inhibits wild-type Staphylococcus aureus RNA polymerase with an IC50 of 34 nM; it effectively suppresses Staphylococcus aureus infections, showing MIC values in the range of 0.008–0.5 μg/mL against 300 clinical isolates of staphylococci and streptococci.